Therapeutics

Top Story

OPUS-3 replicates, confirms OPUS-2 results for lifitegrast

August 11, 2017

OPUS-3 showed significantly improved symptoms of eye dryness with lifitegrast, as measured by eye dryness score, versus placebo in those with dry eye disease.

The 12-week, randomized, double-masked, multicenter, placebo-controlled, phase 3 study included adults at least 18 years old who underwent a 14-day placebo run-in. Participants were randomized 1:1 to lifitegrast ophthalmic solution 5.0% (355 patients) or placebo (356 patients), twice daily for 84 days.

In the Journals

Retinal pigment epithelial cells a potential reservoir for Ebola

August 8, 2017
Human retinal pigment epithelial cells support replication of Ebola virus and release the virus in high titer, according to researchers who studied live Ebola virus and…

BLOG: Approved products for challenging cases needed

August 8, 2017
I have a message for the FDA: What surgeons really need in practicing medicine in the U.S. are approved products for unusual cases. How many orphan procedures would…
In the Journals

Delay between eye drop instillations increases efficacy

August 7, 2017
Researchers recommend that patients with chronic conditions requiring multiple, different eye drops wait 5 minutes between administration, according to a study in…
More Headlines »
COPE

Diabetic Eye Disease - Volume 2, Number 1

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Diabetic retinopathy (DR) is a major cause of blindness among American adults aged 40 years and older. The prevalence…
More »
Video
Meeting News Coverage

VIDEO: Carefully supervise patients when using generics

June 29, 2015
More »
Resource Centers
Optometry's Meeting

Optometry's Meeting

Video
Meeting News

VIDEO: Restasis multidose available soon

November 11, 2016
More »
Advertisement
Advertisement